Voyager Therapeutics Inc

VYGRNASDAQ · USD
3.09USD0.00 (+1.65%)
325

Voyager Therapeutics Inc (VYGR) Wheel Strategy

VYGR wheel strategy scan found 1 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 96.3%.

Read more

Running a VYGR wheel strategy lets you generate consistent premium income on Voyager Therapeutics Inc while setting your own entry and exit prices on the underlying. Voyager Therapeutics Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own VYGR, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best VYGR wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on VYGR, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable VYGR wheel from a losing one.

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.

The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the VYGR wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your VYGR wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.

Jan 15, 20273.00$0.40$0.95-0.321201%51.9%96.3%7

As of September 18, 2026

Run the Wheel on VYGR With Confidence

Find the best VYGR wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.

Start your 14-day free trial